Total Payments
$377,491
2023 Payments
$1,050
Companies
10
Transactions
125
Payment Breakdown by Category
Consulting$221,836 (58.8%)
Other$80,087 (21.2%)
Research$57,129 (15.1%)
Travel$12,235 (3.2%)
Food & Beverage$6,204 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $221,836 | 35 | 58.8% |
| Honoraria | $63,737 | 10 | 16.9% |
| Unspecified | $57,129 | 9 | 15.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,350 | 3 | 4.3% |
| Travel and Lodging | $12,235 | 14 | 3.2% |
| Food and Beverage | $6,204 | 54 | 1.6% |
Payments by Type
General
$320,361
116 transactions
Research
$57,129
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kedrion Biopharma Inc. | $235,218 | 69 | $0 (2021) |
| Shire North American Group Inc | $62,430 | 29 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $61,929 | 9 | $0 (2021) |
| Spark Therapeutics, Inc. | $8,184 | 4 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $3,750 | 2 | $0 (2022) |
| Amgen Inc. | $3,216 | 4 | $0 (2017) |
| BIOVERATIV THERAPEUTICS INC. | $1,607 | 5 | $0 (2018) |
| Davol Inc. | $1,050 | 1 | $0 (2023) |
| Genentech USA, Inc. | $86.14 | 1 | $0 (2017) |
| BioMarin Pharmaceutical Inc. | $19.75 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $1,050 | 1 | Davol Inc. ($1,050) |
| 2022 | $750.00 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($750.00) |
| 2021 | $36,431 | 3 | Kedrion Biopharma Inc. ($19,250) |
| 2020 | $83,523 | 18 | Takeda Pharmaceuticals U.S.A., Inc. ($44,748) |
| 2019 | $93,170 | 22 | Kedrion Biopharma Inc. ($63,877) |
| 2018 | $43,285 | 34 | Kedrion Biopharma Inc. ($23,032) |
| 2017 | $119,281 | 46 | Kedrion Biopharma Inc. ($90,284) |
All Payment Transactions
125 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/05/2023 | Davol Inc. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 04/14/2022 | Bayer HealthCare Pharmaceuticals Inc. | Jivi (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Hematology | ||||||
| 11/09/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,400.00 | General |
| 09/01/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $11,781.25 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | ||||||
| 02/10/2021 | Kedrion Biopharma Inc. | Albuked (Biological), KOATE, GAMMAKED | Consulting Fee | Cash or cash equivalent | $19,250.00 | General |
| Category: Critical Care | ||||||
| 12/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | FEIBA (Biological) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: HEMATOLOGY | ||||||
| 10/22/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| Category: Hematology | ||||||
| 10/02/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $11,005.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | ||||||
| 10/01/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $7,810.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | ||||||
| 10/01/2020 | Takeda Pharmaceuticals U.S.A., Inc. | VONVENDI (Biological) | — | Cash or cash equivalent | $2,128.16 | Research |
| Study: A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE • Category: HEMATOLOGY | ||||||
| 09/18/2020 | Takeda Pharmaceuticals U.S.A., Inc. | VONVENDI (Biological) | — | Cash or cash equivalent | $2,100.00 | Research |
| Study: A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE • Category: HEMATOLOGY | ||||||
| 09/08/2020 | Kedrion Biopharma Inc. | RhoGAM Ultra-Filtered PLUS (Biological), KOATE | Food and Beverage | In-kind items and services | $81.92 | General |
| Category: Obstetrics | ||||||
| 09/02/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Consulting Fee | Cash or cash equivalent | $5,950.00 | General |
| Category: Hematology | ||||||
| 08/03/2020 | Kedrion Biopharma Inc. | RhoGAM Ultra-Filtered PLUS (Biological) | Food and Beverage | In-kind items and services | $165.30 | General |
| Category: Obstetrics | ||||||
| 07/22/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Consulting Fee | Cash or cash equivalent | $5,950.00 | General |
| Category: Hematology | ||||||
| 06/29/2020 | Kedrion Biopharma Inc. | RhoGAM Ultra-Filtered PLUS (Biological), KOATE | Food and Beverage | In-kind items and services | $114.21 | General |
| Category: Obstetrics | ||||||
| 06/02/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $11,005.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | ||||||
| 05/07/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Consulting Fee | Cash or cash equivalent | $5,950.00 | General |
| Category: Hematology | ||||||
| 03/12/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Consulting Fee | Cash or cash equivalent | $5,950.00 | General |
| Category: Hematology | ||||||
| 03/05/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Food and Beverage | In-kind items and services | $113.61 | General |
| Category: Hematology | ||||||
| 02/24/2020 | Kedrion Biopharma Inc. | RhoGAM Ultra-Filtered PLUS (Biological), KOATE | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Obstetrics | ||||||
| 01/30/2020 | Kedrion Biopharma Inc. | KOATE (Biological) | Consulting Fee | Cash or cash equivalent | $7,350.00 | General |
| Category: Hematology | ||||||
| 01/21/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $7,100.00 | Research |
| Study: A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | ||||||
| 09/18/2019 | Kedrion Biopharma Inc. | KOATE (Biological) | Honoraria | Cash or cash equivalent | $5,950.00 | General |
| Category: Hematology | ||||||
| 09/11/2019 | Kedrion Biopharma Inc. | KOATE (Biological) | Honoraria | Cash or cash equivalent | $5,950.00 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | Takeda Pharmaceuticals U.S.A., Inc. | $48,701 | 5 |
| A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $4,228 | 2 |
| A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE | Shire North American Group Inc | $4,200 | 2 |
About Dr. Louis Aledort, MD
Dr. Louis Aledort, MD is a Hematology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861424061.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Louis Aledort, MD has received a total of $377,491 in payments from pharmaceutical and medical device companies, with $1,050 received in 2023. These payments were reported across 125 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($221,836).
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location New York, NY
- Active Since 07/07/2006
- Last Updated 09/11/2025
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1861424061
Products in Payments
- KOATE (Biological) $124,849
- Koate (Drug) $89,375
- Albuked (Biological) $19,250
- VONVENDI (Biological) $6,328
- FEIBA (Biological) $3,613
- Nplate (Biological) $3,216
- Kovaltry (Drug) $3,000
- NO PRODUCT DISCUSSED (Drug) $1,500
- CEPROTIN (Biological) $1,165
- RHOGAM (Drug) $909.03
- Jivi (Drug) $750.00
- RhoGAM Ultra-Filtered PLUS (Biological) $650.86
- Koate (Biological) $184.28
- ALPROLIX (Drug) $107.27
- HEMLIBRA (Biological) $86.14
- ADVATE (Biological) $32.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in New York
Dr. Barry Coller, M.d, M.D
Hematology — Payments: $10.2M
Hematology $10.2M
Dr. Dan Douer, M.d, M.D
Hematology — Payments: $665,161
Hematology $665,161
Michael Mauro, Md, MD
Hematology — Payments: $374,307
Hematology $374,307
Faith Davies, Md, MD
Hematology — Payments: $373,421
Hematology $373,421
Ann Jakubowski, Md, MD
Hematology — Payments: $92,726
Hematology $92,726
Maria Palomba, Md, MD
Hematology — Payments: $70,690
Hematology $70,690